Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT538 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Fate Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
FT538 + pembrolizumab is a combination therapy consisting of FT538, an induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell product, and pembrolizumab, a monoclonal antibody that targets programmed cell death protein 1 (PD-1). **FT538** is engineered for improved cytotoxicity and metabolic fitness, incorporating non-cleavable CD16, CD38 knockout, and IL-15/IL-15 receptor fusion. **Pembrolizumab** blocks the PD-1 immune checkpoint, enhancing T-cell-mediated anti-tumor responses. The combination is designed to maximize immune-driven cancer cell killing and overcome resistance by synergistically activating innate (NK cell) and adaptive (T cell) immune mechanisms. FT538 + pembrolizumab is being explored primarily for advanced hematologic and solid malignancies, with particular interest in settings where immunoresistance is common[1][3][4].
- Other names
- FT538FT-538FT 538Keytrudapembrolizumab
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)PDCD1 (Programmed cell death protein 1 receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on FT538 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT538 + pembrolizumab.